Jessica's Feed
Apr 5, 2011

Valeant seeks to replace Cephalon board; bid rejected

NEW YORK/TORONTO, April 5 (Reuters) – Cephalon Inc (CEPH.O: Quote, Profile, Research, Stock Buzz)
on Tuesday rejected an unsolicited, $5.7 billion acquisition
bid by Canada’s Valeant Pharmaceuticals (VRX.TO: Quote, Profile, Research, Stock Buzz)(VRX.N: Quote, Profile, Research, Stock Buzz), and
Valeant sought to replace the U.S. biopharmaceutical company’s
board of directors.

Cephalon said Valeant’s $73-a-share bid, which Valeant
expects to finance entirely with debt, undervalued the company,
as well as “its key assets and its prospects.”

Apr 5, 2011

Novel M&A paths gain acceptance

NEW YORK (Reuters) – Large pharmaceutical companies may be better-served focusing on unconventional acquisitions and unique uses for drugs rather than on traditional mergers that focus on gross margins and cost-savings.

As pharmaceutical companies struggle with the pending loss of patent protection on their blockbuster drugs, different business strategies have emerged.

Apr 4, 2011

Reuters Summit – Novel M&A paths gaining acceptance

NEW YORK (Reuters) – Large pharmaceutical companies may be better-served focusing on unconventional acquisitions and unique uses for drugs rather than on traditional mergers that focus on gross margins and cost-savings.

As pharmaceutical companies struggle with the pending loss of patent protection on their blockbuster drugs, different business strategies have emerged.

Apr 4, 2011

Novel M&A paths gaining acceptance

NEW YORK (Reuters) – Large pharmaceutical companies may be better-served focusing on unconventional acquisitions and unique uses for drugs rather than on traditional mergers that focus on gross margins and cost-savings.

As pharmaceutical companies struggle with the pending loss of patent protection on their blockbuster drugs, different business strategies have emerged.

Mar 25, 2011

Global crises to soften M&A near-term after strong Q1

PHILADELPHIA/LONDON, March 24 (Reuters) – This year is set
to be a blockbuster for deals, exemplified by mega acquisitions
such as T-Mobile USA or Genzyme, with turmoil in the Middle
East and Japan causing just a temporary slowdown.

Worldwide mergers and acquisitions (M&A) have risen 58
percent so far this year, according to preliminary data from
Thomson Reuters, marking the best start to a year since 2007
and building on last year’s tentative recovery.

Mar 7, 2011

Dealtalk: Barnes & Noble auction gets case of writer’s block

NEW YORK (Reuters) – Barnes & Noble Inc’s (BKS.N: Quote, Profile, Research, Stock Buzz) efforts to find a buyer have slowed to a crawl, erasing recent gains in its stock price, as potential suitors question the bookseller’s ability to compete against formidable rivals.

Barnes & Noble is trying to reinvent itself and has a winner with its Nook e-reader. Its largest direct rival, bankrupt Borders Group Inc BGPIQ.PK, is shrinking by half. Yet the company’s stock has fallen below $12, less than where it was when the company put itself up for sale in August.

Mar 7, 2011

Barnes & Noble auction gets case of writer’s block

NEW YORK, March 7 (Reuters) – Barnes & Noble Inc’s (BKS.N: Quote, Profile, Research, Stock Buzz)
efforts to find a buyer have slowed to a crawl, erasing recent
gains in its stock price, as potential suitors question the
bookseller’s ability to compete against formidable rivals.

Barnes & Noble is trying to reinvent itself and has a
winner with its Nook e-reader. Its largest direct rival,
bankrupt Borders Group Inc BGPIQ.PK, is shrinking by half.
Yet the company’s stock has fallen below $12, less than where
it was when the company put itself up for sale in August.

Mar 2, 2011

Office Depot deal not on the schedule right now

NEW YORK/PHILADELPHIA (Reuters) – Investors looking at Office Depot Inc (ODP.N: Quote, Profile, Research, Stock Buzz) as a near-term buyout candidate are bound to be disappointed.

Analysts and bankers see a slim chance of anyone buying the second-largest U.S. office supplies chain before it finds a permanent chief executive or fixes problems at its home office.

Feb 23, 2011

KKR hikes dividend, economic net income rises

PHILADELPHIA, Feb 23 (Reuters) – Private equity firm KKR &
Co LP (KKR.N: Quote, Profile, Research, Stock Buzz) raised its dividend and said fourth-quarter
earnings rose nearly 39 percent amid stronger investment
returns and capital raising.

Economic net income, a measure used by private equity firms
like the Kohlberg Kravis Roberts & Co parent to report
earnings, was $714.6 million in the fourth quarter, compared
with $515.3 million a year earlier.

Feb 19, 2011

HCA sees IPO in range of $27-$30/share: source

NEW YORK/PHILADELPHIA (Reuters) – Hospital chain operator HCA Inc expects its initial public offering to price at $27 to $30 a share, according to a source familiar with the situation.

HCA is expected to begin its roadshow to market the shares on Tuesday and price the offering on March 9, the source said.